HALONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

HALOZYME THERAPEUTICS, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$122.50+0.66 (+0.54%)

Close on Oct 19, 2026

Market cap: $14.85B
P/E (TTM): 36.1
Dividend yield: –

HALOZYME THERAPEUTICS, INC. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31
Revenue	1,397	1,015	829	660	443	268	196	152	317	147	135	75	55	42	56	14	14
Cost of Revenue	229	159	192	139	81	43	46	10	31	33	29	23	6.25	1.09	0.26	0.99	0.31
Gross Profit	1,168	856	637	521	362	224	150	142	285	113	106	53	49	41	56	13	13
Research & Development	81	79	76	67	36	34	141	150	151	151	93	80	97	70	58	52	57
Selling, General & Admin	207	154	149	144	50	46	77	61	54	46	40	36	32	25	18	15	15
Total Costs & Expenses	928	464	492	393	167	123	264	221	236	230	163	138	135	96	76	68	72
Operating Income	469	551	338	268	276	144	-68	-69	81	-83	-27	-63	-80	-54	-20	-54	-58
Interest Expense	18	18	19	17	7.53	20	12	18	22	20	5.20	5.58	3.27	0	0	–	–
Other Non-Operating Income	21	24	16	1.05	1.10	5.43	6.99	7.58	2.59	1.33	0.42	–	–	0.07	0.07	1.02	0.10
Asset Impairment Charges	–	–	–	–	–	–	–	0	0	0	0	0.20	0	0	0	–	–
Gain (Loss) on Sale of Assets	-2.62	-1.53	-0.61	-0.13	0	0.77	-1.43	-0.01	-0.05	-0.01	-0.01	-0.23	0	-0.01	0.00	-0.01	0.00
Pretax Income	467	557	348	249	249	129	-72	-80	62	-102	-32	-68	–	–	–	–	–
Income Tax Expense	150	113	67	47	-154	0.22	-0.01	0.54	-1.36	1.16	0	0	–	–	–	–	–
Net Income	317	444	282	202	403	129	-72	-80	63	-103	-32	-68	-83	-54	-20	-53	-58
EPS (Basic)(per share)	2.64	3.50	2.13	1.48	2.86	0.95	-0.50	-0.56	0.46	-0.81	-0.25	-0.56	-0.74	-0.48	-0.19	-0.56	-0.67
EPS (Diluted)(per share)	2.56	3.43	2.10	1.44	2.74	0.91	-0.50	-0.56	0.45	-0.81	-0.25	-0.56	-0.74	-0.48	-0.19	-0.56	-0.67
Shares Outstanding (Basic, Weighted)(shares)	120	127	132	137	141	136	144	144	136	128	127	123	113	111	103	–	–
Shares Outstanding (Diluted, Weighted)(shares)	124	129	134	141	147	141	144	144	139	128	127	123	113	111	103	–	–
EBITDA	480	562	349	274	279	148	-64	-67	83	-81	-26	-61	-79	-53	-19	-53	-57
Net Interest Income	–	–	–	–	–	–	–	–	–	–	–	–	–	0.06	0.06	0.05	0.10

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 82.4%
Operating margin: 35.9%
Net margin: 24.9%
Return on equity, FY2025: 153.6%

Financial strength

Current ratio: 2.71
Debt to equity: 14.95
Debt to assets: 83.3%
Cash to current liabilities: 47.4%

Valuation

P/E ratio: 36.1
Price to sales: 8.92
Price to book: 103.45
Dividend yield: –